Get the Stockscreener App
24.61
1.28%
-0.32
After Hours:
24.61
Ideaya Biosciences Inc stock is traded at $24.61, with a volume of 1.05M.
It is down -1.28% in the last 24 hours and up +4.32% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$24.93
Open:
$24.94
24h Volume:
1.05M
Relative Volume:
0.97
Market Cap:
$2.16B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-11.24
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
-9.39%
1M Performance:
+4.32%
6M Performance:
+32.31%
1Y Performance:
-31.85%
1-Day Range:
$24.59
$25.49
1-Week Range:
$23.23
$27.69
52-Week Range:
$13.45
$37.80
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
24.61 | 2.17B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
American Century Companies Inc. Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
190,421 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Cubist Systematic Strategies LLC - MarketBeat
Leerink Partnrs Brokers Decrease Earnings Estimates for IDYA - Defense World
Trexquant Investment LP Has $816,000 Stock Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Trading 5.6% Higher Following Analyst Upgrade - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $38.00 at Royal Bank Of Canada - MarketBeat
IDEAYA Biosciences' (IDYA) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Stephens Reaffirms Overweight Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
Adage Capital Partners GP L.L.C. Sells 12,000 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
How to recover losses in IDEAYA Biosciences Inc. stock2025 Year in Review & Fast Moving Stock Trade Plans - Newser
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.4%What's Next? - MarketBeat
Barclays Begins Coverage on IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
How institutional ownership impacts IDEAYA Biosciences Inc. stock2025 Technical Patterns & High Accuracy Swing Entry Alerts - Newser
Northern Trust Corp Has $12.34 Million Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Receives Overweight Rating from Cantor Fitzgerald - Defense World
Quantitative breakdown of IDEAYA Biosciences Inc. recent move2025 Earnings Surprises & Daily Stock Trend Reports - Newser
Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating - Insider Monkey
Real time breakdown of IDEAYA Biosciences Inc. stock performanceQuarterly Trade Summary & Weekly Watchlist for Consistent Profits - Newser
Chart based analysis of IDEAYA Biosciences Inc. trendsSwing Trade & Reliable Trade Execution Plans - Newser
Trend analysis for IDEAYA Biosciences Inc. this week2025 Key Lessons & Technical Pattern Based Signals - Newser
IDEAYA Biosciences Inc. stock daily chart insightsGlobal Markets & Detailed Earnings Play Alerts - Newser
IDEAYA Biosciences (NASDAQ:IDYA) Now Covered by Analysts at Citizens Jmp - MarketBeat
Can IDEAYA Biosciences Inc. reach all time highs this yearEarnings Recap Summary & Reliable Price Breakout Alerts - Lancaster City Council
Ideaya Biosciences stock price target raised to $38 from $36 at RBC Capital - Investing.com Nigeria
Is IDEAYA Biosciences Inc. a good ESG investmentJuly 2025 Macro Moves & Weekly Setup with ROI Potential - Lancaster City Council
Ideaya touts trio of cancer drugs as it eyes spot in precision oncology market - Endpoints News
Real time alert setup for IDEAYA Biosciences Inc. performanceWeekly Stock Recap & Target Return Focused Picks - Newser
Is it too late to sell IDEAYA Biosciences Inc.2025 Analyst Calls & Technical Confirmation Trade Alerts - Newser
What technical models suggest about IDEAYA Biosciences Inc.’s comebackWatch List & Target Return Focused Picks - Newser
RBC Capital Adjusts Price Target on IDEAYA Biosciences to $38 From $36, Maintains Outperform, Speculative Risk - MarketScreener
Advanced analytics toolkit walkthrough for IDEAYA Biosciences Inc.2025 Key Highlights & Daily Profit Maximizing Trade Tips - Newser
IDEAYA Biosciences Inc. stock volume spike explainedJuly 2025 Patterns & Community Consensus Trade Alerts - Newser
IDEAYA Biosciences Inc. stock momentum explainedJuly 2025 Fed Impact & Safe Investment Capital Preservation Plans - Newser
Ideaya Biosciences stock falls despite positive R&D Day updates - Investing.com
Ideaya Biosciences stock falls despite positive R&D Day updates By Investing.com - Investing.com UK
Will IDEAYA Biosciences Inc. continue its uptrendEarnings Miss & Smart Money Movement Tracker - Newser
IDEAYA reports promising results in urothelial cancer treatment trial By Investing.com - Investing.com Canada
Q3 EPS Estimates for IDEAYA Biosciences Raised by Wedbush - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Will IDEAYA Biosciences Inc. stock go up soonProduct Launch & Verified Momentum Stock Alerts - Newser
Will IDEAYA Biosciences Inc. stock recover after recent dropEarnings Overview Summary & Reliable Price Breakout Alerts - Newser
Can you recover from losses in IDEAYA Biosciences Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - Newser
Using Python tools to backtest IDEAYA Biosciences Inc. strategiesWeekly Trend Recap & Reliable Intraday Trade Plans - Newser
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma - The Malaysian Reserve
How to escape a deep drawdown in IDEAYA Biosciences Inc.Weekly Trade Review & Safe Entry Trade Signal Reports - Newser
IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst - Seeking Alpha
How to track smart money flows in IDEAYA Biosciences Inc.Weekly Profit Report & Weekly Breakout Opportunity Watchlist - Newser
Latham & Watkins Advises IDEAYA Biosciences on Exclusive Licensing Agreement With Servier - Latham & Watkins LLP
IDEAYA reports positive interim data for eye cancer treatment - Investing.com
IDEAYA reports positive interim data for eye cancer treatment By Investing.com - Investing.com Canada
IDEAYA reports promising results in urothelial cancer treatment trial - Investing.com
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):